Literature DB >> 10598122

Tolerance to nitrates with enhanced radical formation suppressed by carvedilol.

B Fink1, M Schwemmer, N Fink, E Bassenge.   

Abstract

Enhanced oxidant stress occurs under many pathophysiologic conditions (e.g., inflammation) and can be induced and mimicked by continuous nitrate therapy, eliciting increases in platelet activity, enhanced formation of reactive oxygen species (ROS), and impaired nitrate-induced vasorelaxation. Analysis was performed of effects of coinfusion of glycerol trinitrate (GTN) either with a carvedilol metabolite with antioxidant properties or with antioxidant vitamin C (Vit-C) on various hemodynamic parameters during enhanced oxidant stress associated with nitrate tolerance. Carvedilol metabolite (BM910228: 4.5 microg/kg/min) or Vit-C (55 microg/kg/min) was coadministered with GTN (1.5 microg/kg/min) for 5 days in chronically instrumented dogs. Changes in coronary diameters (CD) and other hemodynamic parameters were continuously monitored, as well as changes in platelet function. At the beginning of GTN treatment, CD increased by 9.8 +/- 0.4% and progressively declined to basal control values within 3 days. However, with additional antioxidant protection either with BM910228 or with Vit-C, the GTN-induced increase in CD was maintained (8.6 +/- 0.4% or 10.5 +/- 0.6%) and remained elevated for the entire infusion period. The thrombin-stimulated intracellular Ca2+ concentrations of platelets remained nearly unchanged during Vit-C or BM910228 in contrast to the increase with GTN. The basal cyclic guanosine monophosphate (cGMP) contents of platelets after GTN coadministered with BM910228 or with Vit-C increased on day 1 to 233 or to 250% versus control and remained at that level. Additional in vitro tests with xanthine oxidase-induced oxidant stress resulted in a more or less pronounced scavenging of O2- radicals by BM920228, Vit-C, or superoxide dismutase (SOD). Coadministration of carvedilol metabolite BM910228 or of Vit-C along with GTN suppressed noxious effects of GTN-induced oxidant stress such as increased platelet activity and impaired nitrate-induced vasorelaxation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598122     DOI: 10.1097/00005344-199912000-00005

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles.

Authors:  B Mayer; M Beretta
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

2.  Melatonin inhibits nitrate tolerance in isolated coronary arteries.

Authors:  Stephen T O'Rourke; Hana Hammad; Philippe Delagrange; Elizabeth Scalbert; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

3.  Role of glutaredoxin-mediated protein S-glutathionylation in cellular nitroglycerin tolerance.

Authors:  Pei-Suen Tsou; Vamsi Addanki; Jessica A Haas; Nathaniel A Page; Ho-Leung Fung
Journal:  J Pharmacol Exp Ther       Date:  2009-02-17       Impact factor: 4.030

4.  Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study.

Authors:  Beate Aurich-Barrera; Lynda V Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 5.  Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.

Authors:  Andreas Daiber; Thomas Münzel
Journal:  Antioxid Redox Signal       Date:  2015-09-24       Impact factor: 8.401

6.  Mitochondrial oxidative stress and nitrate tolerance--comparison of nitroglycerin and pentaerithrityl tetranitrate in Mn-SOD+/- mice.

Authors:  Hanke Mollnau; Philip Wenzel; Matthias Oelze; Nicolai Treiber; Andrea Pautz; Eberhard Schulz; Swenja Schuhmacher; Kurt Reifenberg; Dirk Stalleicken; Karin Scharffetter-Kochanek; Hartmut Kleinert; Thomas Münzel; Andreas Daiber
Journal:  BMC Cardiovasc Disord       Date:  2006-11-08       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.